Literature DB >> 9140562

Insulin-like growth factor 1 and corticosteroid modulation of chondrocyte metabolic and mitogenic activities in interleukin 1-conditioned equine cartilage.

D D Frisbie1, A J Nixon.   

Abstract

OBJECTIVE: To evaluate potential stimulatory or matrix-sparing effects of insulin-like growth factor 1 (IGF-1), alone or in combination with a corticosteroid, in an interleukin 1 (IL-1)-induced model of cartilage degradation. SAMPLES: Cartilage from the weightbearing surfaces of trochlea and condyles of clinically normal 2-year-old male horses. PROCEDURE: Triamcinolone acetonide and IGF-1 effects were evaluated by assessing: matrix responses by sulfated glycosaminoglycan (GAG) assay and [35S]sulfated GAG synthesis; collagen content by hydroxyproline assay; and mitogenic response by [3H]thymidine incorporation into DNA and fluorometric assay of total DNA concentration.
RESULTS: Conditioning of cartilage explants with 10 ng of human recombinant IL-1 alpha increased degradation and decreased synthesis of matrix proteoglycans (PG), without affecting matrix collagen content. Human recombinant IGF-1 decreased PG loss and reversed the reduction of PG synthesis in cartilage explants conditioned with IL-1. Given alone, steroids decreased PG concentration and synthetic rate in normal cartilage. However, the previously diminished PG content, attributable to IL-1 conditioning, was not further exacerbated by steroid administration in IL-1-conditioned explants. Combined treatment of normal cartilage explants with IGF-1 and steroids resulted in PG preservation and increase in collagen content. Similar PG and collagen effects were not evident when treating IL-1-conditioned cartilage with IGF-1/steroid combinations. Decrease in chondrocyte proliferation was associated with steroid administration. Exposure to IGF and steroids prevented the decrease in mitogenesis that could lead to cellular loss, particularly in IL-1-conditioned explants.
CONCLUSION: Combination IGF-1 and steroid treatment of normal cartilage cultures indicated substantial ability to override the anabolic suppression associated with steroids alone. Potentially, administration of corticosteroids, followed by IGF-1, may act to decrease propagation of detrimental mediator release while allowing appreciation of the chondroenhancing effects of IGF-1. These beneficial effects were considerably reduced in IL-1-induced cartilage damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140562

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  5 in total

1.  Binding and release characteristics of insulin-like growth factor-1 from a collagen-glycosaminoglycan scaffold.

Authors:  Leanne M Mullen; Serena M Best; Roger A Brooks; Siddhartha Ghose; Jessica H Gwynne; John Wardale; Neil Rushton; Ruth E Cameron
Journal:  Tissue Eng Part C Methods       Date:  2010-05-22       Impact factor: 3.056

2.  An ex vivo model using human osteoarthritic cartilage demonstrates the release of bioactive insulin-like growth factor-1 from a collagen-glycosaminoglycan scaffold.

Authors:  J Wardale; L Mullen; D Howard; S Ghose; N Rushton
Journal:  Cell Biochem Funct       Date:  2015-06-09       Impact factor: 3.685

3.  Bioactive IGF-1 release from collagen-GAG scaffold to enhance cartilage repair in vitro.

Authors:  Leanne M Mullen; Serena M Best; Siddhartha Ghose; John Wardale; Neil Rushton; Ruth E Cameron
Journal:  J Mater Sci Mater Med       Date:  2015-01-11       Impact factor: 3.896

Review 4.  Instructive cartilage regeneration modalities with advanced therapeutic implantations under abnormal conditions.

Authors:  Zhonghan Wang; Hanxiang Le; Yanbing Wang; He Liu; Zuhao Li; Xiaoyu Yang; Chenyu Wang; Jianxun Ding; Xuesi Chen
Journal:  Bioact Mater       Date:  2021-11-18

5.  Use of allogeneic freeze-dried conditioned serum for the prevention of degradation in cartilage exposed to IL-1ß.

Authors:  Livia Camargo Garbin; C Wayne McIlwraith; David D Frisbie
Journal:  BMC Vet Res       Date:  2022-07-11       Impact factor: 2.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.